NAP1L1 overexpression has been associated with a poor prognostic outcome and has previously been found to promote cellular proliferation in various neoplastic conditions including colorectal cancer, HCC, lung adenocarcinoma, and neuroendocrine cancers (Zhu et al., 2022). Here, NAP1L1 is linked to hepatocellular carcinoma.